Cytomegalovirus (CMV) is a ubiquitous double-stranded enveloped DNA virus of the Herpesviridae family. Primary infection in immunocompetent individuals is usually asymptomatic or a self-limited disease. CMV resides in various cells as latent infection, which can be reactivated during a period of immunosuppression. CMV seroprevalence varies among different populations, with a higher rate of seroprevalence in developing countries, including Thailand \[[@CIT0001]\].

CMV infection remains a major cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients \[[@CIT0004]\]. Ganciclovir is the antiviral drug of choice for the treatment and prevention of CMV infection. However, the emergence of ganciclovir-resistant CMV infection has been increasingly reported worldwide, particularly among recipients of solid organ transplants \[[@CIT0005]\]. The occurrence of ganciclovir-resistant CMV infection is associated with longer hospitalization and increased morbidity and mortality \[[@CIT0005], [@CIT0009]\]. Previous studies have shown that the risk of developing ganciclovir-resistant CMV is associated with several factors, including but not limited to prolonged exposure to ganciclovir, CMV serostatus of donors and recipients, and type of transplantation \[[@CIT0008]\].

The major mechanisms of ganciclovir resistance in CMV are mutations in the viral kinase and/or DNA polymerase genes. Mutations in the viral UL97 kinase gene confer resistance to ganciclovir, whereas mutations in the UL54 DNA polymerase gene are typically associated with high-level resistance to ganciclovir and cross-resistance to cidofovir and/or foscarnet \[[@CIT0012]\]. Common mechanisms of CMV resistance to ganciclovir have been predominantly described with the UL97 mutation \[[@CIT0015]\]. The majority of UL97 mutations occur at codons 460--607, with mutations at codons 460 and 520 resulting in at least a 5-fold increase in IC50 \[[@CIT0019], [@CIT0020]\]. Despite the currently available information on risk factors and clinical outcomes of patients who are infected with ganciclovir-resistant CMV, data in pediatric patients are still limited. As ganciclovir is the firstline treatment for CMV infection, this study aimed to describe the clinical characteristics of pediatric patients with ganciclovir-resistant CMV infection with UL97 mutations. Additionally, the risk factors and outcomes attributable to this ganciclovir-resistant CMV infection were examined.

METHODS {#s1}
=======

Study Population {#s2}
----------------

This was a retrospective study in which patients' data were collected from January 2013 to September 2017 at a tertiary hospital in Bangkok, Thailand. All pediatric patients who were virologically suspected of ganciclovir-resistant CMV infection were included. Inclusion criteria included patients with CMV reactivation/infection who had not been exposed to ganciclovir or valganciclovir before initiation of treatment and had increasing CMV load or suboptimal responses (increased or failed to decrease to half of the initial viral load) after at least 2 weeks of appropriately dosed intravenous ganciclovir (5-mg/kg/dose twice daily). Patients' demographics, clinical manifestations, laboratory data, antiviral treatment, and outcomes were collected from electronic medical records. The following definitions were used according to the published guidelines \[[@CIT0021], [@CIT0022]\]. CMV infection was defined as evidence of CMV replication regardless of symptoms. CMV disease was defined as patients with evidence of CMV infection with attributable symptoms. CMV disease can be further classified as a viral syndrome (ie, fever, leucopenia, and/or thrombocytopenia), or as a tissue-invasive disease. The study was approved by the Institutional Review Board of the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

CMV Prevention Strategies {#s3}
-------------------------

For solid organ transplant recipients and stem cell transplant recipients, we used preemptive therapy as the main approach for prevention of CMV diseases in all cases in this study. Patients who underwent kidney transplant with serostatus of D+/R-- received intravenous ganciclovir prophylaxis for 2 weeks and had preemptive therapy after that. Patients who underwent liver transplant received only preemptive therapy regardless of CMV serostatus. Weekly monitoring for plasma CMV load was implemented in all patients. During the study period, we used a viral load of 1000 copies/mL as a cutoff value to initiate preemptive therapy.

For patients with hematologic malignancies, plasma CMV load was measured if CMV infection was suspected, and ganciclovir was administered as a preemptive therapy. In addition, if patients required blood transfusion, only leukocyte-poor blood components were used to reduce the risk of transfusion reactions and transmission of CMV.

Laboratory Confirmation of CMV Infection and Ganciclovir-Resistant Diagnosis {#s4}
----------------------------------------------------------------------------

Plasma CMV load was quantified using the quantitative real-time polymerase chain reaction (PCR) technique by COBAS AmpliPrep/COBAS Taqman (Taqman CMV Test; Roche Molecular Diagnostics, Branchburg, NJ, USA). Detection of UL97 gene mutations was achieved by using the LightCycler real-time PCR assay for the simultaneous detection of different UL97 mutations in codons 460 and 520 (Roche Diagnostic, Mannheim, Germany), as previously described \[[@CIT0023]\].

Statistical Analysis {#s5}
--------------------

Descriptive statistics were used for demographic and clinical characteristics. The independent *t* test and Mann-Whitney *U* test were used for comparison of continuous variables between groups. A *P* value of \<.05 was considered statistically significant.

RESULTS {#s6}
=======

Demographic Data {#s7}
----------------

A total of 34 patients who had virologically suspected ganciclovir-resistant CMV infection and blood analyses for UL97 gene mutations were included. Approximately half of all patients were boys. The median age of the patients (interquartile range \[IQR\]) was 7.85 (1.69--14.03) years. The majority of patients were hemato-oncological patients and hematopoietic stem cell transplantation recipients. Eleven patients had CMV tissue invasive diseases, and 9 patients died.

Characteristics of Patients With Ganciclovir-Resistant CMV Infection {#s8}
--------------------------------------------------------------------

Of 34 patients who were suspected of having ganciclovir-resistant CMV infection, 10 patients (29.4%) had genotypically confirmed ganciclovir-resistant CMV infection. None of these patients had received ganciclovir for CMV prophylaxis before diagnosis. The median age (IQR) was 3.02 (0.85--8.68) years. Underlying diseases included 4 solid organ transplant recipients (3 livers, 1 kidney), 1 haploidentical stem cell transplant patient, and 5 hemato-oncological patients (4 with leukemia, 1 with infection-associated hemophagocytic syndrome). Five patients had asymptomatic CMV reactivation, and the other patients had tissue-invasive diseases. Among these solid organ recipients, 2 (50%) patients were D+/R−, and a patient who underwent hematopoietic stem cell transplantation was D−/R−. The clinical characteristics of the patients with ganciclovir-resistant CMV infection are shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical Characteristics of Patients With Ganciclovir-Resistant CMV Infection

  Patient No.   Age, y   Sex   Underlying Diseases   CMV Serostatus   Days of Resistance Testing^a^   Treatment                                       Baseline/ Maximum Creatinine, mg/dL   Outcome
  ------------- -------- ----- --------------------- ---------------- ------------------------------- ----------------------------------------------- ------------------------------------- ------------------------------------
  1             15       M     KT                    D+/R+            15                              HDIV ganciclovir                                0.72/0.95                             Survived
  2             0.96     F     LT                    D+/R−            23                              HDIV ganciclovir, IV cidofovir                  0.13/0.2                              Survived
  3             7        F     ALL                   −                204                             HDIV ganciclovir, IV foscarnet, IV cidofovir    0.25/0.35                             Survived
  4             1.5      M     ANLL                  −                16                              HDIV ganciclovir                                0.31/0.57                             Survived
  5             1.75     M     LT                    D+/R+            22                              HDIV ganciclovir                                0.36/0.46                             Survived
  6             13.7     M     ALL s/p haplo-HSCT    D−R−             12                              HDIV ganciclovir                                0.51/0.77                             Survived
  7             4.6      F     LT                    D+/R−            11                              HDIV ganciclovir                                0.19/0.32                             Died from PTLD
  8             0.5      F     ANLL                  −                31                              HDIV ganciclovir, IV foscarnet, PO artesunate   0.12/0.15                             Died from septicemia
  9             0.17     F     IAHS                  −                31                              HDIV ganciclovir, IV foscarnet                  0.15/0.16                             Died from disseminated CMV disease
  10            4.30     M     ALL                   −                26                              HDIV ganciclovir                                0.13/0.18                             Died from septicemia

Abbreviations: +, seropositivity; −, seronegativity; ALL, acute lymphocytic leukemia; ANLL, acute nonlymphocytic leukemia; CMV, cytomegalovirus; D, donor; F, female; HDIV, high-dose intravenous ganciclovir; IAHS, infection-associated hemophagocytic syndrome; IV, intravenous; KT, kidney transplantation; LT, liver transplantation; M, male; PO, per oral; PTLD, post-transplant lymphoproliferative disorder; R, recipient; s/p haplo-HSCT, status post-haploidentical hematopoietic stem cell transplantation.

^a^Days of resistance testing after initiation of appropriately dosed intravenous ganciclovir.

Ganciclovir-Resistant CMV Infection and Associated Factors {#s9}
----------------------------------------------------------

Ganciclovir resistance was tested at a median time (IQR) of 22.5 (14.3--31) days after initiation of ganciclovir, with a median CMV load (IQR) of 41 100 (13 575--102 346) copies/mL or log 4.61 (4.13--5). All ganciclovir-resistant isolates harbored a UL97 mutation in codon 460. No gene mutation at codon 520 was detected. The median maximum CMV load (IQR) was 113 245 (54 900--1 184 634) copies/mL or log 5.06 (4.74--6.05).

Several variables as potential associated factors for development of ganciclovir-resistant CMV infection were examined. Among all patients, those with ganciclovir-resistant CMV infection were significantly younger than those without the mutation (*P* = .049). The median CMV load at diagnosis and the mean CMV load at the time of gene mutation analysis were not significantly different between those with and those without mutations. In contrast, the maximum CMV viral load was significantly higher in those who harbored a UL97 gene mutation compared with those without this mutation (*P* = .004). Although patients with ganciclovir-resistant CMV infection had a higher rate of end-organ involvement and worse outcomes, these were not significantly different from those with wild-type infection. The demographic data and outcomes of the patients with and without ganciclovir-resistant CMV infection are shown in [Table 2](#T2){ref-type="table"}.

###### 

Demographic Data and Outcomes of Patients With and Without Ganciclovir-Resistant CMV Infection

  Characteristic                                                                      Patients With a UL97 Gene Mutation (n = 10)   Patients Without a UL97 Gene Mutation (n = 24)   *P* Value
  ----------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------ -----------
  Male sex, No. (%)                                                                   5 (50)                                        11 (45.8)                                        .83
  Age, median (IQR), y                                                                3.02 (0.85--8.68)                             10.45 (2.7--16.4)                                .049
  Underlying diseases, No. (%)                                                                                                                                                       
  Hematological malignancy                                                            6 (60)                                        17 (70.8)                                        .553
  Solid organ transplantation                                                         4 (40)                                        7 (29.2)                                         
  CMV load at diagnosis of CMV infection, median (IQR), log copies/mL                 3.8 (2.74--4.48)                              2.92 (2.61--3.75)                                .064
  CMV load at the time of gene mutation analysis, median (IQR), log copies/mL         4.61 (4.13--5)                                3.96 (3.0--4.6)                                  .061
  Maximum CMV load, median (IQR), log copies/mL                                       5.06 (4.74--6.05)                             4.42 (4.03--4.87)                                .004
  Days of anti-CMV resistance testing after initiation of ganciclovir, median (IQR)   22.5 (14.3--31)                               20.5 (16--28.5)                                  .461
  End-organ involvement, No. (%)                                                      5 (50)                                        6 (25)                                           .165
  Mortality, No. (%)                                                                  4 (40)                                        5 (20.8)                                         .315

Abbreviations: CMV, cytomegalovirus; IQR, interquartile range.

Treatment and Outcome of Ganciclovir-Resistant CMV Infection {#s10}
------------------------------------------------------------

Reduction of immunosuppression, along with high-dose ganciclovir up to 7.5 mg/kg per dose twice daily, was implemented in all patients. Six of 10 (60%) patients were successfully treated with high-dose ganciclovir, and the plasma CMV load became undetectable at a median time (IQR) of 23 (17--56) days.

No complications of nephrotoxicity were observed in all patients treated with high-dose ganciclovir. The values for baseline and maximal serum creatinine are shown in [Table 1](#T1){ref-type="table"}. Neutropenia with an absolute neutrophil count (ANC) of \<1000/µL was observed in 6 patients. Granulocyte-colony stimulating factor (G-CSF) was administered in all patients with an ANC of \<500/µL. However, it is worth mentioning that 5 of these 6 patients had underlying diseases of hematologic malignancies and had had neutropenia before initiation of high-dose ganciclovir.

Ganciclovir was switched to foscarnet or cidofovir in 4 patients. Artesunate was added in 1 patient as an adjunctive therapy. Four (40%) patients died, but only 1 patient died from a CMV-related condition (disseminated CMV infection with infection-associated hemophagocytosis syndrome). The remaining patients died from complications that were not directly related to CMV infection, including *Pseudomonas aeruginosa* septicemia, *Klebsiella pneumoniae* septicemia, and post-transplant lymphoproliferative disorder.

DISCUSSION {#s11}
==========

This single-center study examined ganciclovir-resistant CMV infection in a pediatric patients who had never been exposed to ganciclovir and focused on clinical predictors associated with this infection. Almost one-third of the patients who failed to respond to standard ganciclovir treatment developed genotypically confirmed ganciclovir resistance. All ganciclovir-resistant CMV cases in this study harbored a codon 460 mutation in UL97, which was confirmed by a genotypic assay. Interestingly, none of the patients received ganciclovir or valganciclovir for CMV prophylaxis before development of resistance. Therefore, the current data support the assertion that children who are not exposed to anti-CMV drugs may also be at risk of early emergence of ganciclovir-resistant CMV infection.

Although the ganciclovir-resistant phenotype caused by UL97 mutations has been widely described in adults, data on CMV infection with UL97 mutations in pediatric patients are scarce. Previous studies of pediatric patients have reported that the incidence of drug-resistant CMV infection was 2%--5% \[[@CIT0018], [@CIT0024]\]. However, most cases were hematopoietic stem cell and solid organ transplant recipients. To the best of the authors' knowledge, this is the first study to show development of CMV resistance in the pediatric population without prior ganciclovir/valganciclovir exposure. This supports the fact that mutant strain viruses have already existed before initiation of ganciclovir therapy. It is possible that a high initial viral load comprises more resistant strain viruses than a low initial viral load. Thus, a higher number of resistant strain viruses could rapidly predominate after selective pressure from antiviral drugs. This mechanism operates in HIV patients exposed to zidovudine \[[@CIT0027]\].

Generally, a 1-log decline in CMV viral load is expected after at least 2 weeks of appropriate antiviral treatment. Ganciclovir resistance should be considered if patients have persistent viremia, DNAemia, or the CMV viral load continues to increase beyond 2 weeks after initiation of corrected therapy \[[@CIT0006], [@CIT0028], [@CIT0029]\]. Potential risk factors for emergence of CMV drug resistance include prior antiviral exposure, high initial viral load, persistent viral replication, intense immunosuppression, and recurrent episodes of CMV infection \[[@CIT0006], [@CIT0018], [@CIT0026], [@CIT0030], [@CIT0031]\]. The current study shows that patients who were infected with a ganciclovir-resistant CMV strain had a significantly higher maximum viral load than those without the mutation strain. This finding supports previously published studies that have described a high peak CMV viral load as a potential contributor to development of drug-resistant CMV \[[@CIT0015], [@CIT0032]\]. Our results also show that patients infected with the ganciclovir-resistant CMV strain tended to harbor a higher viral load at diagnosis of CMV infection and a higher viral load at the time when ganciclovir resistance was suspected. However, the small sample size of the study precluded the power to demonstrate a statistically significant difference. Our study also demonstrated that patients with ganciclovir-resistant CMV infection were younger than those without resistance. This may reflect the fact that immunity to CMV infection was less active in younger patients. It is well known that patients with absence of preexisting immunity to CMV such as D+/R-- patients in solid organ transplant have a higher risk of acquisition of ganciclovir-resistant CMV infection \[[@CIT0005], [@CIT0008]\]. Therefore, this conclusion requires further confirmation in a study with a greater sample size with multivariate analysis.

The duration of all forms of ganciclovir exposure is also a significant risk factor for development of drug-resistant CMV strains. Drug resistance typically occurs after months of antiviral prophylaxis or therapy. In an adult cohort study, the median accumulative duration of ganciclovir treatment was 151 days before development of virological resistance \[[@CIT0016]\]. Fisher et al. showed that the median time of ganciclovir/valganciclovir exposure in solid organ transplant recipients was 153 days before development of a drug-resistant CMV strain \[[@CIT0015]\]. Another study by Shmueli et al. showed the appearance of resistance after a cumulative treatment duration of 70 days \[[@CIT0030]\]. In contrast, the present study showed that resistance could develop in the early phase after treatment initiation (a median time of ≥22.5 days).

In all cases of suspected or confirmed drug-resistant CMV infection, reduction of immunosuppression remains the firstline strategy to optimize the host immune response. However, this approach may be problematic in some complicated cases. The choices of anti-CMV drugs should be guided by the results of CMV genotypic assays \[[@CIT0029]\]. Generally, CMV isolates that harbor UL97 gene mutations remain susceptible to foscarnet and cidofovir. However, isolates with UL54 gene mutations are more likely to confer cross-resistance to cidofovir. Therefore, foscarnet is recommended as the first option for empirical treatment of suspected ganciclovir-resistant CMV diseases. However, a disadvantage of this option is its potential nephrotoxicity, which requires close monitoring of fluid and electrolytes. Previous studies have demonstrated that dose escalation of ganciclovir (up to 7.5--10 mg/kg twice daily) is also an appealing option to avoid adverse effects associated with foscarnet \[[@CIT0029], [@CIT0033], [@CIT0034]\]. In the absence of UL54 gene mutations, cidofovir is another therapeutic option for drug-resistant CMV, but nephrotoxicity is also a concern. Because foscarnet and cidofovir were not consistently available during the study period, 6 (60%) patients achieved eradication of the virus with high-dose ganciclovir (7.5 mg/kg/dose twice daily) therapy without any evidence of nephrotoxicity. Therefore, high-dose ganciclovir might be a feasible treatment option for infection caused by CMV with UL97 mutation.

The present study has some limitations associated with bias of a retrospective study. First, not all patients, but only those with virologically suspected resistance, were tested for resistance. In addition, the magnitude of ganciclovir-resistant CMV infection among patients who were treated with this drug could not be accurately determined, as the total number of patients who were treated with ganciclovir during this time period was not completely available. Recent data from our center have shown that the overall prevalence of CMV reactivation (CMV viral load ≥20 copies/mL) among pediatric acute lymphoblastic leukemia patients was 50%. However, all treated patients in this study responded well to ganciclovir \[[@CIT0035]\]. For pediatric patients who underwent hematopoietic stem cell transplant, only 1 of 47 patients (2%) treated with ganciclovir had documented ganciclovir-resistant CMV infection. For liver transplant patients, 2 of 40 patients (5%) who were treated with ganciclovir were proven to have ganciclovir-resistant CMV infection. Prospective data collection is needed to elaborate the overall magnitude of ganciclovir-resistant CMV infection in pediatric patients who are being treated with ganciclovir. Second, only mutations in codons 460 and 520 were analyzed in this study, as the primers for detection of other mutations were not available during the study period. Although most UL97 mutations conferring ganciclovir resistance are strongly clustered at codons 460, 520, or 590--607 \[[@CIT0017], [@CIT0036]\], the true incidence of drug-resistant CMV infection was underrated, as only 2 codons were evaluated. Therefore, whole-genome sequencing should be performed in the future. Finally, UL54 gene mutations, which confer cross-resistance to cidofovir, were not evaluated in the current study.

In conclusion, ganciclovir-resistant CMV infection is an emerging problem, not only in pediatric transplanted recipients, but also in hemato-oncological patients. Therefore, screening for mutations should be considered in patients with persistent viremia, even if patients have not previously received ganciclovir prophylaxis. High-dose ganciclovir might be a feasible option for the treatment of ganciclovir-resistant CMV infection when other anti-CMV drugs are not available.
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